Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Diseases

  Free Subscription


27.11.2017

1 Biochem Biophys Res Commun
1 BMC Cancer
1 Dig Dis
1 Eur Radiol
11 Hepatology
3 J Hepatol
1 N Engl J Med
3 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Biochem Biophys Res Commun

  1. YAMAMOTO K, Kuragano T, Kimura T, Nanami M, et al
    Interplay of adipocyte and hepatocyte: Leptin upregulates hepcidin.
    Biochem Biophys Res Commun. 2017 Nov 17. pii: S0006-291X(17)32282.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. GKIKA E, Hallauer L, Kirste S, Adebahr S, et al
    Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
    BMC Cancer. 2017;17:781.
    PubMed     Text format     Abstract available


    Dig Dis

  3. SHI L, Zhang X, Li J, Bai X, et al
    Favorable Effects of Endoscopic Ligation Combined with Drugs on Rebleeding and Mortality in Cirrhotic Patients: A Network Meta-Analysis.
    Dig Dis. 2017 Nov 21. doi: 10.1159/000484082.
    PubMed     Text format     Abstract available


    Eur Radiol

  4. MULE S, Pigneur F, Quelever R, Tenenhaus A, et al
    Can dual-energy CT replace perfusion CT for the functional evaluation of advanced hepatocellular carcinoma?
    Eur Radiol. 2017 Nov 22. doi: 10.1007/s00330-017-5151.
    PubMed     Text format     Abstract available


    Hepatology

  5. LIANG Y, Feng Y, Zong M, Wei X, et al
    beta-Catenin Deficiency in Hepatocytes Aggravates Hepatocarcinogenesis Driven by Oncogenic beta-Catenin and MET.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29661.
    PubMed     Text format     Abstract available

  6. PARK H, O'Brien TR, Rehermann B
    The role of genetics in hepatic fibrosis amongst HCV patients.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29659.
    PubMed     Text format    

  7. SIMON TG, King LY, Chong DQ, Nguyen L, et al
    Diabetes, Metabolic Comorbidities and Risk of Hepatocellular Carcinoma: Results from Two Prospective Cohort Studies.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29660.
    PubMed     Text format     Abstract available

  8. PEI Y, Chen XP, Zhang W
    Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: more details, more significance.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29666.
    PubMed     Text format    

  9. HOOKS KB, Audoux J, Fazli H, Lesjean S, et al
    New insights into diagnosis and therapeutic options for proliferative hepatoblastoma.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29672.
    PubMed     Text format     Abstract available

  10. ZHANG XP, Wang K, Chen ZH, Cheng SQ, et al
    Hepatocellular carcinoma with hepatic vein invasion should not be considered as a contraindication for liver resection.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29665.
    PubMed     Text format    

  11. TOW C, Brown RS Jr, Tafesh ZH, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2017;66:1709-1712.
    PubMed     Text format    


  12. 2017 Hepatology referees (volumes 65 and 66).
    Hepatology. 2017;66:2096-2101.
    PubMed     Text format    

  13. CAST A, Valanejad L, Wright M, Nguyen P, et al
    C/EBPalpha-dependent pre-neoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29677.
    PubMed     Text format     Abstract available

  14. GIANNINI EG, Bucci L, Garuti F, Brunacci M, et al
    Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29668.
    PubMed     Text format     Abstract available

  15. BORZIO M, Dionigi E, Rossini A, Marignani M, et al
    External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. (HEP-17-0903).
    Hepatology. 2017 Nov 22. doi: 10.1002/hep.29662.
    PubMed     Text format     Abstract available


    J Hepatol

  16. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available

  17. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    PubMed     Text format     Abstract available

  18. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    PubMed     Text format     Abstract available


    N Engl J Med

  19. DIEHL AM, Day C
    Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
    N Engl J Med. 2017;377:2063-2072.
    PubMed     Text format    


    Radiology

  20. CHOI SY, Kim SH, Park CK, Min JH, et al
    Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study.
    Radiology. 2017 Nov 21:162846. doi: 10.1148/radiol.2017162846.
    PubMed     Text format     Abstract available

  21. TANG A, Bashir MR, Corwin MT, Cruite I, et al
    Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.
    Radiology. 2017 Nov 21:170554. doi: 10.1148/radiol.2017170554.
    PubMed     Text format     Abstract available

  22. SHAMIR SB, Kurian J, Kogan-Liberman D, Taragin BH, et al
    Hepatic Imaging in Neonates and Young Infants: State of the Art.
    Radiology. 2017;285:763-777.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: